Yesafili (aflibercept-jbvf) - Biocon
Lucentis (ranibizumab) - Roche, Novartis
Fédération France Macula Practical Guidelines for the Use of Anti-VEGF Biosimilars (PubMed, J Fr Ophtalmol) - Sep 25, 2026 - "Anti-VEGF biosimilars are expected to play an increasingly important role in retinal care by expanding treatment accessibility and contributing to healthcare sustainability. Their successful implementation requires a thorough understanding of regulatory requirements, careful patient selection, and continued post-marketing surveillance. These recommendations provide a practical framework for the integration of biosimilars into contemporary retinal practice." 
Clinical guideline • Journal • Ophthalmology • Retinal Disorders
http://www.ncbi.nlm.nih.gov/pubmed/42785194
 
A Miere; C Danese; C J Mehanna; D El Ghazi; E Souied; F Amoroso; H Oubraham; J F Korobelnik; L Kodjikian; M Srour; O Semoun; S Razavi; S Y Cohen
 
Sep 25, 2026
 
Prev Next